Mark Andersen, CFA

Chief Financial Officer

Mark Andersen, CFA, joined FibroBiologics as Chief Financial Officer in June 2022. He is a key member of the FibroBiologics executive leadership team and plays a critical role in the company’s strategic financial decision-making.

He most recently served as Chief Financial Officer and Vice President of Administration for the Indiana Biosciences Research Institute (IBRI) in Indianapolis, overseeing finance, human resources, legal, and administrative functions. While at IBRI, he negotiated a master licensing agreement and in-licensed two patents to help establish a platform diagnostics technology. He also assisted with fundraising and provided oversight for the endowment investment portfolio that grew to nearly $150 million during his tenure. Prior to that, he served as Vice President of Finance and Corporate Controller for a public biomedical company in Georgia where he was responsible for financial accounting and SEC reporting.

He served in various financial leadership positions at Eli Lilly and Company in Global Treasury, Mergers and Acquisitions, Lilly USA, Corporate Financial Reporting, and Global Product Development. At Lilly, he managed investment portfolios, led M&A transactions, provided financial leadership and negotiation support for licensing deals, and directed all financial aspects of a collaborative partnership during the late-stage development and commercial launch of a first-in-class diabetes drug. He started his career in public accounting as an auditor with firms KPMG and Deloitte.

He received his M.B.A. from the University of Michigan Ross School of Business and his B.S. in Accounting and M.S. in Accountancy from Southern Utah University.